How investors killed AstraZeneca’s $400bn megadeal

All NewsAugust 11, 2026

Tie-up with US rival Bristol Myers would have marked return to big pharma mergers

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT